7 Biotech Stocks Wall Street Says Will Double or More

The analyst community can help you home in on Wall Street's best biotech stocks. Right now, they believe these seven stocks will double or more in price by this time next year.

Biotech workers in a lab
(Image credit: Getty Images)

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks – those with no approved products – are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.


Data is as of May 18. Stocks listed in order of potential upside as implied by analysts’ consensus price targets.

To continue reading this article
please register for free

This is different from signing in to your print subscription

Why am I seeing this? Find out more here

Maya Sasson
Contributing Writer, Kiplinger.com
Maya Sasson, originally from San Francisco, California, is a financial blogger focusing on U.S. stocks as well as analyst activity. Before diving into the world of financial writing, she earned a B.S. in Mathematics from Tufts University, and began her career as a data analyst for a software company.